Skip to main content

Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 9th edition of Indian Pharmacopoeia is released by IPC

    Union Minister for Health and Family Welfare and Chemicals and Fertilisers, Dr. Mansukh Mandaviya chaired IPC Conference 2022 and released 9th edition of Indian Pharmacopoeia on 1st July at Vigyan Bhawan, New Delhi.

  • NIPER SAS Nagar student gets Rs. 27.8 lakh annual package

    NIPER SAS Nagar has informed that the highest annual package offered to a student is Rs. 27.8 lakh. Many companies conducted campus interviews for the M.Pharm or Masters students of the batch 2020-22.

  • Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics

    Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction. A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

  • Novartis starts new manufacturing plant in Mumbai

    Novartis starts a new plant in Mumbai to make generic cancer drugs. It said that to reinforce our commitment to improving and extending people’s lives, Sandoz Technical Operations, a Novartis division, inaugurated its manufacturing plant for medicines and therapies at Kalwe in Mumbai today.

    The plant, which marks a new chapter for Sandoz, will further strengthen the company’s operations in India to support growing healthcare needs globally.

  • Higher Protein Intake While Dieting Leads to Healthier Eating

    Eating a larger proportion of protein while dieting leads to better food choices and helps avoid the loss of lean body mass, according to a Rutgers study.

    An analysis of pooled data from multiple weight-loss trials conducted at Rutgers shows that increasing the amount of protein even slightly, from 18 percent of a person’s food intake to 20 percent, has a substantial impact on the quality of the food choices made by the person. The study was published in the medical journal Obesity.

  • Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease ; study finds

    A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

  • Dr. Reddy's Laboratories announces the acquisition of an injectable product portfolio from Eton Pharma

    Dr. Reddy's Laboratories Ltd.announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals, Inc.

  • COVAXIN induces higher neutralising antibody response in children, says study

    New study published in Lancet Infectious Diseases suggests that Bharat Biotech COVID19 vaccine, COVAXIN induces higher neutralising antibody response in children aged 2-18 years. The company had conducted an age de-escalation study to assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, COVAXIN.

  • U.S. FDA issued Form 483 with six observations at Glenmark Pharma

    U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharma's formulation manufacturing facility based out of Baddi, India between June 13, 2022 and June 22, 2022.

    Harish Kuber, Company Secretary & Compliance Officer, Glenmark Pharma said, The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

  • Biological E gets WHO nod for JnJ COVID vaccine production

    Biological E gets the World Health Organisation (WHO) approval to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.

    The Johnson & Johnson COVID-19 vaccine consists of a replication-incompetent recombinant adenovirus type 26 (Ad26) viral vector expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in a stabilized conformation.

Subscribe to Pharma News